Comparison of the medical costs between active surveillance and other treatments for early prostate cancer in Japan using data from the PRIAS‐JAPAN study
Comparison of the medical costs between active surveillance and other treatments for early prostate cancer in Japan using data from the PRIAS‐JAPAN study
复制标题
使用 PRIAS-JAPAN 研究的数据比较日本早期前列腺癌主动监测和其他治疗的医疗费用
DOI：
10.1111/iju.14977
复制
发表时间：
2022
影响因子：
2.6
通讯作者：
Akakura K
中科院分区：
文献类型：
--
作者：
Kato Takuma;Yokomizo Akira;Matsumoto Ryuji;Tohi Yoichiro;Miyakawa Jimpei;Mitsuzuka Koji;Sasaki Hiroshi;Inokuchi Junichi;Matsumura Masafumi;Sakamoto Shinichi;Kinoshita Hidefumi;Fukuhara Hiroshi;Kamiya Naoto;Kimura Ryu;Nitta Masahiro;Okuno Hiroshi;Akakura K
目的比较低危前列腺癌患者主动监测与机器人辅助的腹腔镜前列腺切除术、近距离放射治疗、调强放射治疗和激素治疗的医疗费用。方法对香川大学医院在监测第一年(2010年1月至2020年6月)进行的常规活检和2019年5月至2020年6月进行的近距离放射治疗的费用进行分析。激素治疗费用假设为黄体生成激素释放激素类似物超过5 年的费用。符合主动监测条件的患者的定义依据如下：年龄74 岁，≤T2，格里森评分≤6，前列腺特异性抗原水平≤10 ng/ml，以及1-2个阳性核心。我们根据日本前列腺癌研究小组(J-CAP)的研究和2017年的癌症统计数据估计了日本符合积极监测条件的患者总数。然后，我们使用J-CAP和PRIAS-Japan研究数据计算了符合主动监测条件的患者的5年治疗成本。结果2017年，日本符合主动监测条件的患者数量估计为2808人。监测、前列腺摘除、近距离放射治疗、放射治疗和激素治疗的5年总成本分别为1.65、14.0、4.61、4.04和587万美元。如果每个治疗组有50%和100%的患者选择主动监测作为初始治疗，总治疗费用将分别减少689万美元(8.89亿日元)和1380万美元(17.8亿日元)。结论将主动监测扩大到符合条件的前列腺癌患者有助于节省医疗成本。
ObjectivesTo compare the medical costs of active surveillance with those of robot‐assisted laparoscopic prostatectomy, brachytherapy, intensity‐modulated radiation therapy, and hormone therapy for low‐risk prostate cancer.MethodsThe costs of protocol biopsies performed in the first year of surveillance (between January 2010 and June 2020) and those of brachytherapy and radiation therapy performed between May 2019 and June 2020 at the Kagawa University Hospital were analyzed. Hormone therapy costs were assumed to be the costs of luteinizing hormone‐releasing hormone analogs for over 5 years. Active surveillance‐eligible patients were defined based on the following: age <74 years, ≤T2, Gleason score ≤6, prostate‐specific antigen level ≤10 ng/ml, and 1–2 positive cores. We estimated the total number of active surveillance‐eligible patients in Japan based on the Japan Study Group of Prostate Cancer (J‐CAP) study and the 2017 cancer statistical data. We then calculated the 5‐year treatment costs of active surveillance‐eligible patients using the J‐CAP and PRIAS‐JAPAN study data.ResultsIn 2017, number of active surveillance‐eligible patients in Japan was estimated to be 2808. The 5‐year total costs of surveillance, prostatectomy, brachytherapy, radiation therapy, and hormone therapy were 1.65, 14.0, 4.61, 4.04, and 5.87 million United States dollar (USD), respectively. If 50% and 100% of the patients in each treatment group had opted for active surveillance as the initial treatment, the total treatment cost would have been reduced by USD 6.89 million (JPY 889 million) and USD 13.8 million (JPY 1.78 billion), respectively.ConclusionExpanding active surveillance to eligible patients with prostate cancer helps save medical costs.
登录
查看更多内容
DOI：
10.6004/jnccn.2015.0009
发表时间：
2015-01-01
影响因子：
13.4
作者：
Aizer, Ayal A.;Gu, Xiangmei;Nguyen, Paul L.
通讯作者：
Nguyen, Paul L.
DOI：
--
发表时间：
2010
期刊：
Journal of the National Comprehensive Cancer Network : JNCCN
影响因子：
--
作者：
J. Mohler;R. Bahnson;B. Boston;J. E. Busby;A. D'Amico;J. Eastham;C. Enke;D. George;E. Horwitz;R. Huben;P. Kantoff;M. Kawachi;M. Kuettel;P. Lange;G. Macvicar;E. Plimack;J. Pow-Sang;M. Roach;E. Rohren;B. Roth;D. Shrieve;Matthew R. Smith;S. Srinivas;P. Twardowski;P. Walsh
通讯作者：
J. Mohler;R. Bahnson;B. Boston;J. E. Busby;A. D'Amico;J. Eastham;C. Enke;D. George;E. Horwitz;R. Huben;P. Kantoff;M. Kawachi;M. Kuettel;P. Lange;G. Macvicar;E. Plimack;J. Pow-Sang;M. Roach;E. Rohren;B. Roth;D. Shrieve;Matthew R. Smith;S. Srinivas;P. Twardowski;P. Walsh
影响因子：
23.4
作者：
Sathianathen, Niranjan J.;Konety, Badrinath R.;Kuntz, Karen M.
通讯作者：
Kuntz, Karen M.
影响因子：
2.4
作者：
Onozawa, Mizuki;Hinotsu, Shiro;Akaza, Hideyuki
通讯作者：
Akaza, Hideyuki
影响因子：
3.8
作者：
Sanghera S;Mohiuddin S;Coast J;Garfield K;Noble S;Metcalfe C;Lane JA;Turner EL;Neal D;Hamdy FC;Martin RM;Donovan JL;ProtecT study group
通讯作者：
ProtecT study group